[Effect of jiangya capsule on levels of serum nitric oxide synthase activity, malondialdehyde, plasma neuropeptide Y and homocysteine in patients with senile simple systolic hypertension]

What Was Tested

Researchers studied Neuropeptide Y in this randomized controlled trial publication.

To observe the effect of Jiangya Capsule (JYC) on serum levels of nitric oxide synthase (NOS) activity and malondialdehyde (MDA), and plasma concentration of neuropeptide Y (NPY) and homocysteine (Hcy) in patients with senile simple systolic hypertension.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Randomized, double-blinded controlled method was adopted, the patients were divided into two groups, the treated group treated with JYC and the control group treated with Nimodipine.

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Neuropeptide Y study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Neuropeptide Y study, the assignments were hidden from both participants and investigators until the end.

Changes of blood pressure, serum level of NOS and MDA, and plasma concentration of NPY and Hcy were observed.

What Was Measured

The subject headings attached to it are Capsules, Drugs, Chinese Herbal, Homocysteine, Hypertension, Malondialdehyde, Neuropeptide Y and Nitric Oxide Synthase.

What This Means in Plain Language

The paper is a randomized and double-blind study of Neuropeptide Y.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2003 (Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine), a journal based in China.

More context: the Neuropeptide Y compound page, all human trials.